关于JAZZ公司情况

我自己认为光看图是不行的，一定要对公司的FA了如指掌，这样才能灵活运用TA，甚至领先TA指标出现之前预测这个指标出现。
这是JAZZ的公司情况，看看他有多少东西啊，无论是资金还是产品都很支持这个公司股票上行，而从同行业类比的话他的价格明显stock price undervalued

Jazz Pharmaceuticals, Inc. Completes $7 Million Private Placement
July 7, 2009
Jazz Pharmaceuticals, Inc. announced the signing and closing of a private placement of an aggregate of 1,895,734 units, comprised of an aggregate of 1,895,734 shares of common stock and warrants to purchase up to 947,867 additional shares of common stock for aggregate gross proceeds of approximately $7 million. The per unit purchase price for a share of common stock and a warrant to purchase 0.50 of a share of common stock was $3.6925. The warrants have an exercise price of $4.00 per share and are exercisable for seven years. The gross proceeds of the private placement were $7.0 million, and the Company intends to use the proceeds for general corporate purposes. The units were purchased by funds affiliated with Longitude Capital. In connection with the transaction, Patrick Enright, a Managing Director of Longitude Capital, joined Jazz Pharmaceuticals' Board of Directors.
Jazz Pharmaceuticals, Inc. and UCB Announces Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
June 24, 2009
Jazz Pharmaceuticals, Inc. and UCB announced positive preliminary top-line results from the second of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. Confirming the positive results from the first Phase III study, this international, placebo-controlled trial of sodium oxybate to treat fibromyalgia achieved its key endpoints. As in the first randomized, double-blind fibromyalgia study, sodium oxybate significantly decreased pain and fatigue and improved daily function and patient global impression of change. Sodium oxybate has not been evaluated by regulators for the treatment of fibromyalgia and is not approved for this use. The second 14-week Phase III trial, conducted in the United States and seven European countries, included 573 adult patients with fibromyalgia randomized to one of three treatment arms: sodium oxybate 4.5 g/night, sodium oxybate 6 g/night, or placebo. The primary outcome measure, viewed by both U.S. and E.U. regulatory authorities as a clinically meaningful endpoint, was the proportion of patients who achieved at least 30 percent reduction in pain from baseline to endpoint based on the Pain Visual Analog Scale (VAS). Data from the Fibromyalgia Impact Questionnaire (FIQ) are considered equally relevant as Pain VAS data in the E.U. FIQ data are considered supportive data by U.S. regulators.
Jazz Pharmaceuticals, Inc. Puts Three Drug Candidates On Hold To Help Service Debt-Reuters
June 19, 2009
Reuters reported that Jazz Pharmaceuticals, Inc. has put the development of three drugs in its pipeline on hold, in a bid to save cash as it seeks to resolve interest payment issues with its bond holders. The Company, which currently markets sleep disorder drug Xyrem and social anxiety disorder treatment Luvox CR, plans to continue the development of its experimental drug to treat fibromyalgia, a chronic pain syndrome. The fibromyalgia drug is currently being studied in a second late-stage trial. The three halted candidates were in development as treatments for epilepsy and bipolar disorder; to treat restless legs syndrome; and as a treatment for epilepsy in patients who continue to have seizures while on stable anti-epileptic regimens.
Jazz Pharmaceuticals, Inc. Announces Phase III Results
June 15, 2009
Jazz Pharmaceuticals, Inc. announced that its sodium oxybate (JZP-6) demonstrated statistically significant and clinically meaningful improvement in pain and the core symptoms associated with fibromyalgia. These data have not been evaluated by the FDA or other regulatory authorities for use of sodium oxybate in the treatment of fibromyalgia. The 14-week randomized, double-blind, placebo-controlled study included 548 adult patients with fibromyalgia randomized to one of three treatment arms: sodium oxybate 4.5 g/night, sodium oxybate 6 g/night or placebo. The primary outcome measure was the proportion of patients who achieved at least 30% reduction in pain from baseline to endpoint based on the Pain Visual Analog Scale (VAS). At three months, 54.2% (p Jazz Pharmaceuticals, Inc. Announces Changes In Management
April 2, 2009
Jazz Pharmaceuticals, Inc. announced that Samuel R. Saks, its Chief Executive Officer and a member of its Board of Directors, has resigned from both positions, effective as of April 3, 2009. Dr. Saks will serve as a consultant to the Company on medical and clinical matters after his departure. The Board of Directors has appointed Bruce C. Cozadd as the Company's Chief Executive Officer.The Board of Directors also appointed Robert M. Myers, Jazz Pharmaceuticals' President, to the Board of Directors to fill the vacancy on the Board of Directors created by Dr. Saks' resignation.

所有跟帖： 

• 其实你如果注意一个股票了，不用来这里问该不该买，或者发生什么了 -没钱交学费- ♀ (66 bytes) () 07/27/2009 postreply 14:41:51

• 哇！MM FA TA全能，功夫了得 -kx- ♀ (0 bytes) () 07/27/2009 postreply 14:45:12

• 我帖子里边的话怎么不显示啊 -没钱交学费- ♀ (88 bytes) () 07/27/2009 postreply 14:47:11

• 哦，我让版主把它们删了，呵呵 -yumeng- ♂ (30 bytes) () 07/27/2009 postreply 14:53:00

• 显示啊. 我看到了. -crvDriver- ♀ (0 bytes) () 07/27/2009 postreply 14:56:22

• 闻道有先后，术业有专攻，问总比不问好 -PowerfulPlay- ♂ (0 bytes) () 07/27/2009 postreply 15:13:03

• 回复：关于JAZZ公司情况 -arizona001- ♂ (38 bytes) () 07/27/2009 postreply 14:44:36

• 聪明的MM.学习了，谢谢分享！ -让利润飞奔- ♀ (0 bytes) () 07/27/2009 postreply 14:57:44

• 回复：关于JAZZ公司情况 -kx- ♀ (105 bytes) () 07/27/2009 postreply 14:58:50

• 奥,看错了。它已经融到资了，谢谢 -kx- ♀ (0 bytes) () 07/27/2009 postreply 15:07:13